DermatologyNews.net

Dermatology Xagena

The results of a phase I study in advanced melanoma suggested complementary clinical activity with Nivolumab ( Opdivo ), a PD-1 checkpoint inhibitor, plus Ipilimumab ( Yervoy ), a CTLA-4 checkpoint in ...


Keytruda ( Pembrolizumab ) is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with ...


Rosmarinus officinalis L. is a medicinal plant with diverse activities including enhancement microcapillary perfusion. A study has investigated the clinical efficacy of rosemary oil in the treatment ...


Phase II trial results from investigational compound BI 655066 were presented at 73rd Annual Meeting of the American Academy of Dermatology. Nearly double the percentage of patients with moderate-to ...


In clinical practice, patients with psoriasis may require intermittent therapy as part of their long-term treatment programme. Those achieving Physician's Global Assessment ( PGA ) of less than or equ ...


Finasteride ( Propecia ) at a dose of 1 mg/d has been reported to show no significant improvement in 30–50% of patients with androgenetic alopecia. Dutasteride ( Avodart ), a dual inhibitor of both ...


The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7-20%. The use of tumor necrosis factor-alpha ( TNF-alpha ) inhibitors as a treatment for refractory uveitis is ...


The phase IIIb CLEAR study for Secukinumab ( Cosentyx ) has demonstrated superiority to Ustekinumab ( Stelara ) and met its primary endpoint of achieving PASI 90, which represents clear or almost clea ...


Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-alpha therapy on the mechanisms associate ...


Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program were presented at the 23rd European Academy of Dermatology and Venereolog ...


The Dermatologic and Ophthalmic Drugs Advisory Committee ( DODAC ) to the US Food and Drug Administration ( FDA ) has voted unanimously to support the approval of AIN457 ( Secukinumab ), a selective i ...


Results from a phase 2b dose-ranging study of Dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema were presented. All ...


Results from a phase 3 pivotal study demonstrating that Adalimumab ( Humira ) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa ( HS ), specifi ...


Thiazolidinediones ( also known as glitazones ) have shown to be efficacious with a favorable safety profile when used in the treatment of chronic plaque-type psoriasis. The aim of a study was to ...


Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial. Researchers have evaluated outcomes in 2001 patients with primary cutaneous melan ...


In the BRIM-3 trial, Vemurafenib ( Zelboraf ) was associated with risk reduction versus Dacarbazine ( Deticene ) of both death and progression in patients with advanced BRAFV600 mutation-positive mela ...


Results from two pivotal phase III studies evaluating the interleukin-17A ( IL-17A ) inhibitor Secukinumab ( AIN457 ) were published in the New England Journal of Medicine ( NEJM ). Secukinumab met ...


A meta-analysis has evaluated the efficacy and safety of Ustekinumab ( Stelara ) in the therapy of plaque psoriasis. The efficacy was estimated using relative risk of Psoriasis Area and Severity In ...


Certain acne treatments can, in rare instances, cause severe allergic reactions that are potentially life-threatening. The Food and Drug Administration ( FDA ) is warning that the use of certain acne ...


Bristol-Myers Squibb ( BMS ) has announced that a randomized blinded comparative phase 3 study evaluating Nivolumab versus Dacarbazine ( DTIC ) in patients with previously untreated BRAF wild-type adv ...


A man with almost no hair on his body has grown a full head of it after a novel treatment by clinicians at Yale University. There is currently no cure or long-term treatment for alopecia universalis, ...


Psoriasis is an inflammatory disorder, which has been reported to be associated with cardiovascular risks. Although increased cardiovascular risks in psoriasis are well established, there are no data ...


A post hoc analysis has examined the effects of Adalimumab ( Humira ) in patients with scalp and/or nail psoriasis from BELIEVE, a randomized, controlled, multicentre phase 3 safety and efficacy trial ...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...


Tofacitinib ( Xeljanz ) is a novel, oral Janus kinase inhibitor currently under investigation for plaque psoriasis. This exploratory analysis of a phase IIb, 12-week, dose-ranging study has evaluat ...


Vismodegib ( Erivedge ), a first-in-class Hedgehog pathway inhibitor, was Food and Drug Administration ( FDA ) approved for advanced basal cell carcinomas ( BCCs ) based on a single, nonrandomized, ph ...


OBSERVE-5 was a 5-year FDA-mandated surveillance registry of patients with psoriasis. Researchers have assessed long-term Etanercept ( Enbrel ) safety and effectiveness. Patients with moderate to s ...


Vismodegib ( Erivedge ), the first Food and Drug Administration ( FDA )-approved Hedgehog ( Hh ) signaling pathway inhibitor, in the treatment of advanced basal cell carcinoma ( BCC ). Activation o ...


A phase III study of the combination of Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), compared to single agent therapy with Dabrafenib in patients with BRAF V600 E or K mutation positive unrese ...


Fungal skin infections, or dermatomycoses, are associated with a broad range of pathogens. Involvement of gram-positive bacteria is often suspected in dermatomycoses. Inflammation plays an important r ...


Apremilast ( Otezla ), a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. Apremilast's effect on patient-reported outcomes ( PROs ) i ...


Patients with advanced melanoma, who have been treated with the monoclonal antibody, Ipilimumab ( Yervoy ), can survive for up to ten years, according to the largest analysis of overall survival for t ...


Psoriasis is a common and chronic immune-mediated inflammatory disease of the skin affecting approximately 2% of individuals of European descent with a strong genetic susceptibility. Classic lesions ...


Many patients with chronic idiopathic urticaria ( also called chronic spontaneous urticaria ) do not have a response to therapy with H1-antihistamines, even at high doses. In phase 2 trials, Omalizuma ...


The results from the head-to-head phase III FIXTURE study showing Secukinumab ( AIN457 ), an interleukin-17A ( IL-17A ) inhibitor, was significantly superior to Etanercept ( Enbrel ) in moderate-to-se ...


Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlativ ...


The European Commission has granted conditional approval to Erivedge ( Vismodegib ) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma ( BCC ) or locally advanced BCC ...


The results from the phase 3 trial in melanoma, which has evaluated the efficacy and safety of Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to trea ...


The statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase III studies. ESTEEM 1 ...


Researchers at Columbia University Medical Center ( CUMC; United States ) have devised a hair restoration method that can generate new human hair growth, rather than simply redistribute hair from one ...


Researchers from UCLA's Jonsson Comprehensive Cancer Center reported that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melan ...


Apremilast ( Otezla ), a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily ha ...


Phase II data, published in the New England Journal of Medicine ( NEJM ), have showen that Ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe p ...


The BRAF inhibitor Vemurafenib ( Zelboraf ) represents a new standard of care for metastatic melanoma patients with BRAF V600 mutations after showing improved progression free and overall survival in ...


Preliminary data from a pivotal phase 2 clinical trial of PLX4032 ( RG7204, Vemurafenib, Zelboraf ) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients, are present ...


Raptiva ( Efalizumab ) is an immunosuppressive, humanized monoclonal antibody indicated for treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to ...


There is no evidence probiotics can relieve the symptoms of eczema, but there is some evidence that they may occasionally cause infections and gut problems. These findings from The Cochrane Library co ...


Researchers at Washington University School of Medicine in St. Louis have discovered seven new sites of common DNA variation that increase the risk of this skin condition. They also found that variati ...


A study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of Ustekinumab ( Stelara ) achieved at least a 75 percent reduction in psoriasis at we ...


Two clinical trials of Humira ( Adalimumab ), REVEAL and CHAMPION, have demonstrated promising results in psoriasis. Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati